Osteoarthritis is a highly prevalent joint disease that leads to cartilage breakdown, pain and disability, yet there are still no FDA-approved treatments that can slow or reverse its progression. RNA-based therapies hold great promise because they can silence the molecular signals that drive cartilage degeneration. However, for these treatments to work, they must reach the damaged regions, called lesions, within the cartilage.
